Articles tagged with Fibrosis
Researchers have developed a suite of parameters that can be used to quantitatively measure different physical characteristics of the lung. The parameters were found to be highly sensitive and specific for diagnosing fibrosis and edema in an animal model, using only five necessary parameters.
Researchers at UCLA Health found that reducing inflammation may not influence the extent of liver fibrosis in MAFLD. The study suggests that other pathways could be more effective in targeting fibrosis and improving outcomes for patients.
A research group developed a long-acting artificial hepatocyte growth factor (HGF) mimetic molecule using cyclic peptides and protein engineering. The molecule improved liver fibrosis, lipid accumulation, and inflammation in a mouse model with non-alcoholic steatohepatitis (NASH), providing an option for NASH therapeutics.
Research reveals the critical role of epigenetic regulation in hepatic stellate cell activation and liver fibrogenesis. Key findings include DNA methylation, histone modifications, and non-coding RNAs modulating HSC activation, with potential therapeutic implications for NAFLD.
A new compound developed by researchers at MUSC Hollings Cancer Center has shown promise in improving response to chemotherapy in preclinical models. The compound inhibits the protein lysyl oxidase, preventing it from producing a stiff environment around tumors and allowing drugs to penetrate better.
Researchers created a new cell model to study the effects of senescence on lung fibroblasts. Senescent alveolar epithelial cells triggered fibrotic activation in lung fibroblasts, which was attenuated by senolytic therapy.
These disorders, including CHF, CD, CS, ALGS, and BA, result from genetic mutations affecting bile formation and transport. Management focuses on symptom control, prevention of complications, and definitive treatment with liver transplantation when indicated.
A team of researchers has discovered a mechanism by which the liver's immune cells are suppressed in chronic hepatitis B, leading to organ damage. The 'sleep timer' function allows immune cells to weaken their activity over time, preventing them from proliferating excessively and causing further damage.
Researchers at Chiba University have discovered a new mechanism of ILC2 immune cell development, which may exacerbate allergic diseases. The study found that the induction of GATA3 expression by an ILC2-specific super-enhancer is essential for ILC2 differentiation.
A large-scale study confirms the rising incidence of eosinophilic esophagitis (EoE) in Japan, with a significant increase in cases between 2005 and 2022. The study found an incidence rate of 2.82 per 100,000 person-years and a prevalence rate of 10.68 per 100,000 people.
Scientists have identified a critical genetic mechanism driving cardiac fibrosis and found a novel target for its reversal. The discovery sheds light on the role of transforming growth factor-beta (TGFβ) and ATP-citrate lyase (ACLY) in promoting excessive tissue scarring, providing hope for new heart failure treatments.
Researchers found increased liver oxidative stress and impaired antioxidant defenses in a DS murine model. The study suggests potential therapeutic strategies targeting oxidative stress and lipid metabolism to prevent or mitigate liver-related complications.
Researchers from Aarhus University have developed a method that can detect the earliest changes in the kidney when scar tissue begins to form. This technology uses hyperpolarized 13C-pyruvate MRI to track fibrosis formation, allowing doctors to start treatment earlier and potentially prevent damage.
FM0807 reduces blood glucose levels, improves liver function, and decreases kidney damage in diabetic mice. The compound also inhibits inflammatory markers and alters SMAD2/3 expression, suggesting a protective role in regulating JAK2/STAT3 and TGF-β1/SMAD2/3 signaling pathways.
Researchers found that pentraxin 3 is a non-invasive biomarker for severe fibrosis and increased carotid intima-media thickness in patients with MAFLD. Elevated PTX3 levels were associated with advanced fibrosis and larger CIMT values.
Researchers created an integrated cellular map of a mouse model heart, pinpointing cells and pathways involved in fibrosis. The study identified myofibroblasts as the major drivers of scarring, but also discovered a 'matrifibrocyte' form that may prevent scar resolution.
This study found that TIMP-1 induces the expression of transcription factor Fli-1, which elevates MCP-1 expression and promotes hepatic macrophage recruitment. siRNA-TIMP-1 alleviated liver fibrosis by reducing macrophage migration and MCP-1 expression.
Researchers have developed a novel patch that can help liver tissue regenerate and inhibit inflammation. The patch demonstrated restored liver function in lab tests and promoted recovery from liver fibrosis in rats, showing great potential for treating liver diseases.
A new study has found that FAPI PET/CT is more effective than FDG in predicting progressive pulmonary fibrosis in ILD patients. The study's results suggest that FAPI PET/CT can identify high-risk patients who require closer monitoring or preventive treatment.
Researchers at UTEP have developed a new therapeutic approach to treat skin and lung fibrosis by targeting and rehabilitating cells responsible for the disease. The nanoparticles successfully modified the cells to stop producing excess collagen, offering hope for improved treatments and enhanced quality of life.
Researchers developed a human pancreatic cancer fibrotic barrier model to assess treatment strategies and test efficacy of therapeutic interventions. Inhibition of ROCK2 pathway resulted in reduced ECM remodeling and improved tissue permeability for drugs, highlighting its potential for enhancing drug delivery in PDAC.
Researchers found that tumor-associated macrophages respond to physical properties of fibrosis by synthesizing injury-associated collagens, resulting in metabolic changes that suppress CTL function. This provides an alternative explanation for why anti-tumor immunity is impaired in fibrotic solid tumors.
Researchers found that mitochondrial GRIM19 loss induces liver fibrosis through NLRP3/IL33 activation via reactive oxygen species/NF-кB signaling. This mechanism may provide potential therapeutic approaches for preventing early-stage liver fibrosis.
A new study reveals TNIK's role in various diseases, including fibrosis, cancer, obesity, and Alzheimer's. The protein has been found to drive cancer cell proliferation and treatment resistance, while also regulating metabolic processes.
Researchers developed adhesive hydrogel coatings that eliminate fibrosis, a common issue with medical implants. The coatings bind devices to tissue and prevent the immune system from attacking them.
A phase 3 trial found that pamrevlumab did not significantly improve lung function in patients with idiopathic pulmonary fibrosis. The study's results underscore the need for effective treatments to slow disease progression and improve patient outcomes.
Twendee X reduces oxidative stress, improves skin and lung health, and suppresses fibrosis in SSc mouse models. The supplement's antioxidant effects are likely more potent than individual compounds alone.
Researchers at MCG's Vascular Biology Center have identified a new treatment target for age-related macular degeneration (AMD), a leading cause of blindness. Targeting the adenosine receptor 2A (Adora2a) may block excessive blood vessel growth and fibrosis, potentially offering a more efficient treatment than current therapies.
A study published in Environmental Research found a significant association between black carbon particles and cardiac fibrosis, a marker of heart disease. The risk is higher for hypertensive individuals, with smokers facing the highest risks among non-hypertensive individuals.
Researchers found a three-component signaling pathway in hepatic stellate cells that leads to collagen production and liver fibrosis. A novel RNA-based treatment, ASO, was designed to block this pathway, preventing fibrosis without side effects.
Researchers developed a new experimental strategy to tackle scarring and fibrosis by releasing enough collagen to prevent tissue damage while protecting it from excessive amounts. The strategy, which uses molecules known as peptides to block the export of collagen from cells, shows promise in treating conditions such as scleroderma.
Researchers at Michigan Medicine discovered a pathway that reverses idiopathic pulmonary fibrosis (IPF), a common type of lung scarring. The study found that inhibiting the molecular brake MKP1 is essential for spontaneous resolution of fibrosis, offering new hope for patients with IPF.
A team of researchers at Weill Cornell Medicine has discovered a critical protein sensor called SEL1L that regulates collagen clearance from tissue. This finding provides new insights into the development of therapeutic strategies for diseases like lung fibrosis, which currently have no effective treatments.
Research reveals a dynamic pattern of gene expression in liver fibrosis, with persistent effects even during regression. The study identifies key 'hub' genes that could be developed into biomarkers for future therapies.
Researchers at UVA Health discovered a potential blood test to predict patients with severe COVID-19 who are likely to recover well and those at risk of long-term lung problems. The study found that patients with late-resolving symptoms had fewer immune cells in their blood, correlating with symptom severity.
Researchers used generative AI to design a lead molecule for treating fibrosis, a biological process associated with aging. The compound, INS018_055, demonstrated significant efficacy in preclinical studies and showed promising results in clinical trials, accelerating drug discovery and providing new therapeutic options.
A new computer model of a human lung is being used to simulate the interaction of radiation with lung tissue at a cellular level. This could lead to more targeted treatments for cancer and reduce damage caused by radiotherapy.
Researchers at NDORMS identified how cells work to resolve frozen shoulder, opening up potential new targets for treatment. The study found that distinct populations of macrophages in the shoulder capsule promote tissue remodelling and reduce inflammation.
A VUB research team has identified a specific protein, GPR176, that contributes to liver fibrosis. The discovery opens up possibilities for developing new drugs to treat this condition.
Research from the German Cancer Research Center reveals that repetitive changes in female reproductive organs over time lead to chronic inflammation and fibrosis, which may contribute to increased uterine cancer risk. The study mapped the effects of estrous cycle, pregnancy, and aging on the reproductive tract.
A new study found that one bacterial species, Streptococcus mitis, dominates in IPF patients not treated with antibiotics and is associated with better lung function and survival. This protective relationship does not apply to patients who received antibiotics.
Researchers at University of Virginia Health System developed a new approach to machine learning that identifies drugs minimizing harmful scarring after heart attacks. The tool predicts and explains drug effects for other diseases as well.
A new 3D bioprinted liver tissue model has been developed to study nonalcoholic steatohepatitis (NASH), a serious complication of nonalcoholic fatty liver disease (NAFLD). The model, created using liver cells from healthy or NASH-diseased donors, displays all characteristics of the disease, including fibrosis.
A groundbreaking study identifies FAM3C as a key regulator of breast cancer progression within the tumor microenvironment. The overexpression of FAM3C promotes breast cancer cell survival and metastasis, while its depletion inhibits tumor growth in genetically engineered mouse models.
The University of Rochester is establishing a new NIH-funded center focused on developing FDA-qualified drug development tools related to barrier functions in disease. Researchers will create microphysiological systems with ultrathin membranes of human cells, aiming to reduce animal trials and improve drug efficacy.
A new technique, CLivD score, has been developed to improve liver fibrosis treatment. The study found that the CLivD score can identify at-risk individuals, reducing the need for further evaluation and streamlining screening. This approach holds promise for early detection of liver disease and preventing complications.
Researchers found that higher levels of omega-3 fatty acids in the blood plasma were associated with better lung function and longer survival without needing a lung transplant. This was consistent regardless of smoking history or cardiovascular disease.
Researchers at IRB Barcelona discover iron accumulation as a driver of pathological senescence and fibrosis, highlighting its role in various fibrotic disorders. The study identifies potential methods for non-invasive assessment and treatment of fibrotic diseases via MRI and chemical compounds.
Duke-NUS scientists have discovered a universal pattern in macrophages that form scars across various organs. They found two groups of macrophages with opposing roles: one promoting fibrosis and another dismantling it, which could lead to new therapies for fibrotic diseases.
Researchers discovered that RvD2, a specialized proresolving lipid mediator, can alleviate established liver scarring or fibrosis. Treatment with RvD2 improved liver histopathology and increased bone marrow and blood monocytes.
Researchers found intestinal hormones can inactivate liver's star-like cells responsible for scar tissue formation. This discovery could lead to new treatments targeting cell changes, avoiding severe side effects.
Researchers have made significant progress in understanding a pathway contributing to liver fibrosis. Paxillin has been found to play a key role in the activation of hepatic stellate cells, leading to excessive extracellular matrix production and scarring. This discovery holds promise for developing new treatments for liver fibrosis.
Researchers found a total of 4,721 proteins altered with age in the murine ovary, including upregulated ECM proteins associated with fibrosis. Age-dependent changes also affect immune response pathways and unique immune cell populations.
A new study reveals FGF18 as a key inducer of hepatic stellate cell proliferation and liver fibrosis. FGF18 levels are dramatically elevated in fibrotic livers, and its overexpression induces liver fibrosis in mice.
A University of Virginia team has developed a new analytical tool using hydrogels to cultivate vascular sprouting from mouse lung tissue, providing new insight into idiopathic pulmonary fibrosis. The research aims to understand the biomechanical and biochemical cues to blood vessels in the lungs during disease progression.
Five lung stem cell variants dominate CF lungs, causing inflammation, fibrosis, and mucin secretion. CFTR modulators fail to suppress these inflammatory variants, suggesting they as key targets for new drugs.
A new study found that living donor liver transplant access optimizes the timing of transplant for older, frail cirrhosis patients. Patients with moderate to severe frailty, short stature, and low MELD scores benefited from LDLT, reducing waitlist mortality and improving post-transplant outcomes.
Researchers at Boston University School of Medicine have identified abnormal interactions between platelets and immune cells that promote lung fibrosis. Blocking histones using antibodies alleviated the disease, providing novel mechanistic insights into its development.
Researchers at Nagoya University developed a unique supramolecule to remove cholesterol from macrophages, stopping the development of non-alcoholic steatohepatitis (NASH) in mice. Cholesterol crystals are also found in human patients, suggesting a potential therapeutic strategy.
Researchers aim to identify genetic risk factors and mechanisms underlying virus-induced asthma, using artificial intelligence-based techniques and patient-derived models. The study may lead to personalized prevention campaigns and mechanism-targeted drugs.